GC005 The Patient Is Critically Ill - Intensive Care Medicine; Unstable Vital Organ Function

The lecture presents the following service model ^[1]:

• Ventilated patients commonly receive 1:1 nursing; selected lower-acuity patients may receive 1:2 nursing.
• Most nurses should have post-registration ICU training and competence in advanced life support.
• A full-time medical director leads sufficient specialist staff, preferably working full time in intensive care.
• In Hong Kong, intensivists may have anaesthesiology or physician training backgrounds before specialist critical-care training.
• The medical team also contributes to management, administration, teaching, research, audit, and outreach.

These ratios describe the lecture/CICM standard; actual staffing and dependency definitions remain service- and jurisdiction-specific. The safety principle is that staffing must match patient acuity and the immediacy of required interventions.

One diagram contrasts the older organ-by-organ model with a critical-care model ^[1]. Cardiologists, nephrologists, respiratory physicians, surgeons, and oncologists bring essential disease-specific expertise, but severe illness often crosses these boundaries. The intensivist coordinates simultaneous problems—such as shock, respiratory failure, AKI, delirium, nutrition, and infection—while continuing to work with the relevant specialty teams.

Another diagram makes the dependency explicit:

“Nobody knows everything” is not a weakness of intensive care; it is the reason multidisciplinary teamwork and humility are core safety features.

The lecture cites a 2002 observational study comparing monitored patients in intermediate-care areas with low predicted-risk ICU patients. Mortality was 3.1% in the intermediate-care group and 2.3% in the ICU group ^[1][2]. The groups and care settings differed, so this does not prove that ICU location caused the difference. Its teaching value is narrower: a monitor cannot assess a patient, troubleshoot equipment, interpret changing physiology, or deliver time-critical treatment. ICU benefit comes from the whole response system.

Organ support may:

1. Salvage function before irreversible injury—for example, restoring perfusion in shock.
2. Buy time for recovery—for example, ventilation while treatable lung injury improves.
3. Enable definitive treatment—for example, supporting circulation while source control is achieved.

Organ support is a bridge to an agreed clinical goal, not a treatment for the underlying cause by itself. Its indication should be reassessed when the disease trajectory or the patient's goals change.

The image-heavy slide deliberately spans multiple specialties: circulatory and respiratory failure, AKI, neurological and oncological emergencies, liver failure, trauma and metabolic emergencies, obstetric critical illness, and severe infection. The point is not to memorize a separate machine for every specialty. It is to recognize that different diseases converge on a limited set of failing vital functions.

The patient–doctor–machine diagram also shows cytokine adsorption. This should be understood as a technology depicted in the lecture, not routine treatment for septic shock. The 2026 Surviving Sepsis Campaign suggests against blood-purification techniques such as haemoperfusion, high-dose haemofiltration, or plasma exchange for sepsis or septic shock outside a separate established indication. ^[4]

The monitoring slide shows synchronized ECG, arterial-pressure, and central-venous-pressure waveforms, plus a radial arterial catheter ^[1]. Their meaning is complementary:

For fluid decisions in septic shock, current guidance favors dynamic assessment—for example passive leg raising or a small fluid challenge with change in stroke volume/pulse pressure—over examination or static measures alone. ^[4]

The Queen Mary Hospital AICU photograph labels the ventilator, monitor, infusion pumps, heating device, and an ECMO circuit ^[1]. The visual lesson is the density of interacting systems:

• Infusion pumps permit precise delivery of vasopressors, sedation, analgesia, insulin, and antimicrobials.
• A ventilator supports gas exchange but introduces risks such as ventilator-associated injury, pneumonia, sedation exposure, and immobility.
• A heating device helps prevent or treat hypothermia.
• VV-ECMO primarily provides gas exchange; VA-ECMO can provide both gas exchange and circulatory support. Both are resource-intensive rescue therapies for carefully selected patients, not simply “more powerful ventilation.”

Physiological support may be continued while a possible donation pathway is assessed. Death determination, treatment decisions, referral, consent, and organ-allocation processes must remain properly safeguarded. Donation potential should not distort the patient's prior treatment or the independent determination of death.

• SIRS is not the current definition of sepsis, but it may still be used as a screening signal.
• qSOFA is a simple prognostic bedside score, not a sepsis definition and not recommended as the sole screening tool.
• Current guidance favors NEWS/NEWS2, MEWS, or SIRS over qSOFA when a single hospital screening tool is used, and emphasizes that sepsis remains a clinical diagnosis. ^[4]

For Madam A BC, the practical priorities are ^[4]:

• treat sepsis and septic shock as a medical emergency;
• obtain cultures as soon as possible and ideally before antimicrobials if this does not cause a harmful delay;
• administer antimicrobials immediately, ideally within one hour, when septic shock is present;
• measure lactate and reassess perfusion clinically;
• use crystalloids for resuscitation, but individualize volume and reassess frequently rather than giving repeated fixed boluses automatically;
• start vasopressors promptly when required—peripheral initiation can avoid delay—with norepinephrine first line and an initial MAP target around 65 mmHg for most adults;
• achieve anatomical source control as soon as medically and logistically practical; the current guideline suggests ideally within six hours when source control is required.

Her return to theatre, washout, and diversion are therefore part of the definitive treatment; ICU support cannot compensate for uncontrolled peritoneal contamination.

The slide is a linear spectrum, not a bell curve:

Too well for ICU  ←  mild — moderate — severe — very severe  →  too ill to benefit

The admission zone lies where ICU-level treatment has a reasonable prospect of improving an outcome the patient values. Both boundaries are uncertain:

• A patient who initially appears too well may deteriorate.
• A patient with very severe illness may recover despite a poor population-level prognosis.
• Scores such as SOFA and APACHE estimate risk in groups; they do not determine an individual's outcome.
• Reversibility and treatment response become clearer over time.

When benefit is uncertain, an agreed time-limited trial may be reasonable: define the treatments being tried, patient-centered goals, a review time, and what improvement, deterioration, or non-response will mean. It is not a guaranteed ICU admission and should not become treatment without an endpoint. Current sepsis guidance supports early goals-of-care discussion but notes insufficient evidence to recommend routine formal time-limited trials for all patients. ^[4]

The slide explicitly asks whether ICU care should be offered as an option and what happens if the patient cannot decide ^[1]. A safe framework is:

1. Assess capacity for this decision at this time. Capacity is decision- and time-specific; shock, delirium, hypoxia, sedatives, or pain may impair it.
2. If capable: explain expected benefits, burdens, alternatives, and uncertainty. Respect informed consent or refusal.
3. If incapable: look for a valid and applicable advance medical directive and reliable prior wishes; otherwise decide in the patient's best interests with input from the appropriate responsible/eligible person and family.
4. In an emergency: immediately necessary treatment may begin while information and decision-makers are sought, subject to the patient's known valid refusal.
5. Document and review the reasoning as the clinical situation evolves.

In Hong Kong, the Advance Decision on Life-sustaining Treatment Ordinance (Cap. 651) took effect on 31 July 2026. Current Hospital Authority guidance and statutory forms should be used for advance medical directives and DNACPR decisions. ^[9][10][11]

The lecture lists DNACPR and limitation or withdrawal of vasopressors, blood products, ventilator settings, and renal replacement ^[1]. These are not interchangeable:

• DNACPR applies only to CPR after cardiorespiratory arrest. It does not automatically limit antibiotics, oxygen, symptom relief, dialysis, ventilation, or any other treatment.
• Each treatment limitation requires its own indication, discussion, documentation, and review.
• Withholding and withdrawing life-sustaining treatment are ethically equivalent when the treatment no longer has sufficient justification; withdrawal is not euthanasia—the underlying disease causes death. ^[10]
• Comfort care, communication, nursing, symptom control, and family support continue throughout. Non-abandonment is active care, not merely the absence of CPR.

The slide's historical statement that more than half of ICU deaths are associated with a DNAR decision or treatment limitation should be treated as context from the lecture, not a universal current rate; practice varies by patient population, unit, jurisdiction, and era.

For an incapable adult without an applicable advance directive, current Hospital Authority guidance frames the decision around best interests, considers prior wishes and the input of the responsible/eligible person and family, and does not place the medical decision solely on relatives. Disagreement should trigger further communication, senior/ethics input, and appropriate conflict-resolution processes. ^[10][11]